Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease.
Animals
Antibodies, Viral
/ blood
CD8-Positive T-Lymphocytes
/ immunology
Epitopes, T-Lymphocyte
Female
Influenza Vaccines
/ administration & dosage
Alphainfluenzavirus
/ immunology
Mice
Mice, Inbred BALB C
Orthomyxoviridae Infections
/ immunology
Recombinant Fusion Proteins
/ genetics
Respiratory Syncytial Virus Infections
/ immunology
Respiratory Syncytial Virus Vaccines
/ administration & dosage
Respiratory Syncytial Virus, Human
/ genetics
Vaccines, Attenuated
Live attenuated influenza vaccine
Respiratory syncytial virus
T cell immunity
Vaccine enhanced disease
Viral vector
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
04
03
2019
revised:
01
05
2019
accepted:
02
05
2019
pubmed:
11
5
2019
medline:
13
6
2020
entrez:
11
5
2019
Statut:
ppublish
Résumé
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory disease in young children, elderly and immunocompromised adults. There is no licensed vaccine against RSV although development of an effective and safe RSV vaccine has been a high priority for several decades. Among the various vaccine platforms, the viral-vectored RSV vaccines based on licensed cold-adapted live attenuated influenza vaccine (LAIV) might offer an advantage of inducing adequate mucosal CD8 T cell immunity at the infection site of respiratory pathogens. We constructed two recombinant LAIV viruses expressing immunodominant T-cell epitopes of RSV M2-1 protein. The results in this study provide evidence that RSV CD8 T cell epitopes delivered by LAIV viral vector could confer protection against RSV infection without causing pulmonary eosinophilia and inflammatory RSV disease in mice. In addition, these chimeric LAIV-RSV vaccines retained their attenuated phenotype and ability to protect against virulent influenza virus, thus providing a unique approach to fight against two dangerous respiratory viral pathogens using a single vaccine preparation.
Identifiants
pubmed: 31075351
pii: S0166-3542(19)30121-4
doi: 10.1016/j.antiviral.2019.05.001
pmc: PMC6620116
mid: NIHMS1529207
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Epitopes, T-Lymphocyte
0
Influenza Vaccines
0
Recombinant Fusion Proteins
0
Respiratory Syncytial Virus Vaccines
0
Vaccines, Attenuated
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9-17Subventions
Organisme : NIAID NIH HHS
ID : R01 AI093772
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI105170
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI119366
Pays : United States
Organisme : NIAID NIH HHS
ID : R41 AI134132
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.
Références
J Immunol Methods. 2007 Oct 31;327(1-2):63-74
pubmed: 17716680
J Gen Virol. 2001 Nov;82(Pt 11):2663-2674
pubmed: 11602778
Virology. 2018 May;518:313-323
pubmed: 29574336
J Virol. 2011 Jun;85(12):5782-93
pubmed: 21471228
Bull Exp Biol Med. 2016 Aug;161(4):533-7
pubmed: 27590768
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
J Exp Med. 1997 Aug 4;186(3):421-32
pubmed: 9236194
Lancet Infect Dis. 2018 Oct;18(10):e295-e311
pubmed: 29914800
Mucosal Immunol. 2017 Mar;10(2):545-554
pubmed: 27220815
N Engl J Med. 2005 Apr 28;352(17):1749-59
pubmed: 15858184
J Virol. 2008 Mar;82(5):2350-7
pubmed: 18094185
Hum Vaccin Immunother. 2017 Nov 2;13(11):2594-2605
pubmed: 28854003
J Virol. 2001 Oct;75(19):8899-908
pubmed: 11533153
PLoS One. 2011;6(4):e18556
pubmed: 21602908
Curr Opin Virol. 2013 Aug;3(4):468-74
pubmed: 23806514
Expert Rev Vaccines. 2018 Nov;17(11):977-987
pubmed: 30365908
Antiviral Res. 2014 Oct;110:115-23
pubmed: 25110201
J Immunol. 2007 Oct 15;179(8):5415-24
pubmed: 17911628
J Microbiol. 2017 Nov;55(11):900-908
pubmed: 29076066
Clin Vaccine Immunol. 2016 Jan 27;23(3):186-8
pubmed: 26818954
Curr Top Microbiol Immunol. 2013;372:3-38
pubmed: 24362682
Viruses. 2013 Nov 22;5(11):2881-97
pubmed: 24284879
Mol Ther Methods Clin Dev. 2015 May 20;2:15018
pubmed: 26015988
Vaccine. 2010 Nov 23;28(50):8015-25
pubmed: 20934458
Bull Exp Biol Med. 2019 Mar;166(5):631-636
pubmed: 30903496
Expert Rev Vaccines. 2016 Oct;15(10):1241-3
pubmed: 27385419
Clin Vaccine Immunol. 2014 May;21(5):722-31
pubmed: 24648485
Proc Am Thorac Soc. 2005;2(2):110-5
pubmed: 16113477
Sci Transl Med. 2015 Aug 12;7(300):300ra127
pubmed: 26268314
Toxicol Pathol. 2009 Feb;37(2):249-55
pubmed: 19181630
J Biol Chem. 2014 Jun 20;289(25):17406-15
pubmed: 24802755
Am J Epidemiol. 1969 Apr;89(4):422-34
pubmed: 4305198
J Infect Dis. 2017 May 15;215(10):1527-1535
pubmed: 28368530
Virology. 2017 Nov;511:142-151
pubmed: 28846899
JCI Insight. 2016 Jul 7;1(10):
pubmed: 27468427
BMC Vet Res. 2013 Jun 21;9:123
pubmed: 23800279
Clin Microbiol Rev. 2017 Jan;30(1):277-319
pubmed: 27903593
PLoS Pathog. 2018 Jan 2;14(1):e1006810
pubmed: 29293660
PLoS Pathog. 2015 Mar 13;11(3):e1004757
pubmed: 25769044
Hum Vaccin Immunother. 2018;14(12):2964-2970
pubmed: 30024831
Bioengineered. 2013 Jan-Feb;4(1):9-14
pubmed: 22922205
J Immunol. 1993 Aug 15;151(4):2032-40
pubmed: 8345194